Dose titration and confirmation tests for determination of cesticidal efficacy of epsiprantel in dogs.
Fifty-five dogs, naturally infected with Taenia sp or Dipylidium caninum or both, were assigned to the following treatment groups for dose titration studies with epsiprantel: nonmedicated control dogs (n = 14), medicated dogs given a dosage of 2.75 mg/kg of body weight (n = 15), medicated dogs given a dosage of 5.5 mg/kg (n = 16), and medicated dogs given a dosage of 8.25 mg/kg (n = 10). Medication was given orally in a tablet formulation. Feces were examined for cestodes passed and the gastrointestinal tract was examined at necropsy for retained cestodes. Efficacy of epsiprantel was 92.9% against Taenia and 44.8% against Dipylidium for a dosage of 2.75 mg/kg, 100% against Taenia and 99.8% against Dipylidium for a dosage of 5.5 mg/kg, and 94.6% against Taenia and 100% against Dipylidium for a dosage of 8.25 mg/kg. For dose confirmation, 36 dogs naturally infected with Taenia sp or D caninum or both were allotted to 2 treatment groups: nonmedicated control dogs (n = 16) and dogs medicated with epsiprantel at a dosage of 5.5 mg/kg (n = 20). Efficacy was 100% for both Taenia sp and D caninum.
Department of Veterinary Microbiology, College of Veterinary Medicine, University of Missouri, Columbia 65211.
R M
RM
Corwin
S P
SP
Green
T J
TJ
Keefe
D000818:Animals; D000923:Anticestodal Agents / Q000627:therapeutic use*; D002589:Cestoda / Q000187:drug effects; D002590:Cestode Infections / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy* / Q000469:parasitology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005243:Feces / Q000469:parasitology; D011223:Praziquantel / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013621:Taenia / Q000187:drug effects; D013622:Taeniasis / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*
D000923:Anticestodal Agents; C060885:epsiprantel; D011223:Praziquantel